Donald Small, MD

Dr. Stacy Cooper is the Director of the Pediatric Hematologic Malignancy Program, Director of the Pediatric Hematology/Oncology Fellowship Program, and Clinical Director of the Pediatric Oncology Inpatient Program at the Johns Hopkins School of Medicine. Dr. Cooper received her undergraduate degree in Biology and Spanish at the University of Notre Dame. She earned her M.D. at SUNY Upstate Medical University. She completed her general pediatric residency and chief residency at the Johns Hopkins School of Medicine. She completed her pediatric hematology-oncology fellowship with the Johns Hopkins-National Institutes of Health. Dr. Cooper joined the Johns Hopkins faculty in 2015. Her research focuses on clinical research in acute lymphoblastic leukemia, as well as medical education scholarship related to fellowship training. Dr. Cooper is a member of the American Board of Pediatrics, the American Society of Hematology, the American Society of Pediatric Hematology Oncology and the Association of Pediatric Program Directors.

Gastroenterologist Mouen Khashab specializes in therapeutic endoscopy, and he oversees this group of practitioners across the Johns Hopkins enterprise. Nationally and internationally known in the field of interventional endoscopy, Dr. Khashab has contributed immensely to the field’s advancement as a minimally invasive means to treat gastrointestinal and pancreaticobiliary disorders. Dr. Khashab earned his medical degree from the American University of Beirut Faculty of Medicine, and subsequently completed a residency in internal medicine and a fellowship in gastroenterology at Indiana University. He then completed a two-year fellowship at The Johns Hopkins Hospital before joining the faculty in 2011. A busy researcher, Dr. Khashab has published more than 600 papers in peer-reviewed journals. In 2013, he described the procedure called gastric peroral endoscopic myotomy (known as G-POEM) and was able to disseminate and teach it all over the world. Other procedures that he expanded include peroral endoscopic myotomy (POEM), peroral endoscopic myotomy with fundoplication (POEM-F), Zenker’s peroral endoscopic myotomy (Z-POEM) and full thickness resection. In 2022, he received the Master Endoscopist Award from the American Society for Gastrointestinal Endoscopy (ASGE) for his numerous contributions to the field. His procedural expertise includes endoscopic retrograde cholangiopancreatography (ERCP), endoscopic ultrasound (EUS), interventional EUS, submucosal endoscopy, POEM/achalasia, endoscopic mucosal resection, endoscopic submucosal dissection, luminal stenting, large polyp resection and Barrett’s therapy, among others. Dr. Khashab is involved with multiple gastrointestinal societies and has served on many committees, including the ASGE Standards of Practice Committee, which is in charge of formulating guidelines for the practice of endoscopy. He has also served as an associate editor for the journal Endoscopy, a premier journal in the field. Khashab is a highly sought-after speaker at national and international conferences, and he has participated in multiple live endoscopy conferences. Outside of academic medicine, Dr. Khashab is an entrepreneur. His major interest is in new technology and medical devices, and his goal is to disrupt the field by introducing technology that makes endoscopic procedures safer, easier, efficient and more scalable.

Dr. Zambidis is Associate Professor of Oncology and Pediatrics at the Johns Hopkins University School of Medicine, and a member of the Johns Hopkins Kimmel Cancer Center. Dr. Zambidis’ clinical expertise is in the treatment of disorders of the immune system, histiocytic disorders, hematologic malignancies, blood and bone marrow transplantation (BMT), and regenerative medicine. His research interest focuses on advancing our understanding of pluripotent stem cells– the ‘master’ stem cells that can generate any new cell or tissue that the body needs to repair itself. Dr. Zambidis earned his M.D./Ph.D. in the Medical Scientist Training Program at the University of Rochester, Rochester, N.Y. He completed his Pediatrics Residency in the Department of Pediatrics, Washington University, St. Louis, Missouri, and his clinical/research fellowships in Pediatric Hematology/Oncology at the Johns Hopkins Hospital and the National Cancer Institute at the NIH. Dr. Zambidis has been interested in the biology of stem cells since he came to Johns Hopkins, in 2001. As a Pediatric Hematology/Oncology fellow, he was one of the very first Hopkins investigators to work with human embryonic stem cells (hESCs), beginning shortly after they were made available to the biomedical research community, in 2002. Dr. Zambidis was awarded the first NIH K08 Clinician-Scientist Training Award specifically investigating the therapeutic potential of human pluripotent stem cells (2004). After joining the Hopkins faculty, in 2005, he developed an experimental model of the early formation process of human blood and blood vessels using human pluripotent stem cells.The Zambidis laboratory at the Johns Hopkins Institute for Cell Engineering focuses on understanding the developmental biology of human hemato-vascular and human pluripotent stem cells. More recently, his group completed studies on highly efficient methods for generating nonintegrated, human induced pluripotent stem cell (hiPSC) lines from myeloid progenitors. His group has developed novel hiPSC-based vascular therapies for retinopathies, and more recently derived a new class of human pluripotent stem cells in a naïve ground state with new functionalities with even greater potency and stronger regenerative capacities. As a BMT physician-scientist, his long-term goal is to use hESC, hiPSC, and related pluripotent stem cell technologies to not only treat severe degenerative diseases, but also to elucidate the biological nature of cancer and aging.